1. Home
  2. NVAX vs SPRY Comparison

NVAX vs SPRY Comparison

Compare NVAX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • SPRY
  • Stock Information
  • Founded
  • NVAX 1987
  • SPRY 2015
  • Country
  • NVAX United States
  • SPRY United States
  • Employees
  • NVAX N/A
  • SPRY N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • SPRY Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVAX Health Care
  • SPRY Health Care
  • Exchange
  • NVAX Nasdaq
  • SPRY Nasdaq
  • Market Cap
  • NVAX 1.3B
  • SPRY 1.1B
  • IPO Year
  • NVAX 1995
  • SPRY N/A
  • Fundamental
  • Price
  • NVAX $8.32
  • SPRY $9.74
  • Analyst Decision
  • NVAX Hold
  • SPRY Strong Buy
  • Analyst Count
  • NVAX 5
  • SPRY 4
  • Target Price
  • NVAX $9.80
  • SPRY $31.25
  • AVG Volume (30 Days)
  • NVAX 4.6M
  • SPRY 2.5M
  • Earning Date
  • NVAX 11-11-2025
  • SPRY 11-12-2025
  • Dividend Yield
  • NVAX N/A
  • SPRY N/A
  • EPS Growth
  • NVAX N/A
  • SPRY N/A
  • EPS
  • NVAX 2.54
  • SPRY N/A
  • Revenue
  • NVAX $1,078,718,000.00
  • SPRY $112,339,000.00
  • Revenue This Year
  • NVAX $60.81
  • SPRY N/A
  • Revenue Next Year
  • NVAX N/A
  • SPRY $186.14
  • P/E Ratio
  • NVAX $3.38
  • SPRY N/A
  • Revenue Growth
  • NVAX 9.22
  • SPRY 22367.80
  • 52 Week Low
  • NVAX $5.01
  • SPRY $9.34
  • 52 Week High
  • NVAX $11.55
  • SPRY $18.90
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 45.77
  • SPRY 37.87
  • Support Level
  • NVAX $8.02
  • SPRY $9.75
  • Resistance Level
  • NVAX $8.83
  • SPRY $10.38
  • Average True Range (ATR)
  • NVAX 0.47
  • SPRY 0.56
  • MACD
  • NVAX -0.09
  • SPRY -0.01
  • Stochastic Oscillator
  • NVAX 15.03
  • SPRY 4.12

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: